Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer

(2012) A. Sheri et al.   ANNALS OF ONCOLOGY

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

(2012) Andrea Cavazzoni et al.   CANCER LETTERS

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

(2011) Manfred Kaufmann et al.   ANNALS OF SURGICAL ONCOLOGY

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

(2011) Peter A Fasching et al.   BMC CANCER

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

(2011) Milvia Zambetti et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

(2011) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

(2010) Nadia Margariti et al.   BREAST CANCER RESEARCH AND TREATMENT

A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer

(2010) Marco Colleoni et al.   EUROPEAN JOURNAL OF CANCER

Reply to M. Ozsahin et al

(2010) George P. Canellos   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

(2008) Ute E Krainick-Strobel et al.   BMC CANCER

Increase in response rate by prolonged treatment with neoadjuvant letrozole

(2008) J. Michael Dixon et al.   BREAST CANCER RESEARCH AND TREATMENT

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer

(2008) Daniele Generali et al.   JOURNAL OF CLINICAL ONCOLOGY

Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions

(2008) A. Berruti et al.   ONCOLOGIST